ONLINE ZOOM EVENT The Future of the COVID-19 Pandemic: What Happens Next?
Thursday, October 22, 2020
8:00pm HKT on Zoom
Nearly 10 months since the first reported outbreak in mainland China, the coronavirus has continued its rampage. The world is anxiously awaiting an approved and viable vaccine to protect against a pathogen that has killed more than one million people and infected more than 39 million globally. Still, many questions linger, including how long the pandemic will last, whether cities like Hong Kong face the prospect of a new virus wave, and what could come next as winter looms in the Northern Hemisphere. A panel of experts will discuss what they’ve learned so far, the risks that communities face, and what mysteries about the coronavirus remain. Moderated by FCC correspondent board governor, Kristine Servando.
This is one in a series of FCC panel discussions focusing on coronavirus.
Panelists include:
Dr. Sarah Borwein is a general practitioner who co-founded the Central Health Group and has been practicing family medicine in Hong Kong for more than 15 years. Dr. Borwein ran the Infection Control program for the only expatriate hospital in Beijing during the SARS outbreak.
Prof. Ivan Hung is a clinical professor and assistant dean in the University of Hong Kong’s Department of Medicine. Educated at the University of Bristol, he specializes in infectious diseases, gastroenterology and hepatology, with a special research interest in vaccines and innovative treatment of severe influenza. He is also a fellow of the Royal Colleges of Physicians of London and Edinburgh, as well as a board and founding member of the World Association for Infectious Diseases and Immunological Disorders.
Prof. John Nicholls is a clinical professor in pathology at the University of Hong Kong. He graduated from the University of Adelaide and moved to Hong Kong in 1988, launching research into the relationship between viruses and the respiratory tract. He was part of the research team at the University of Hong Kong which isolated and characterized the SARS coronavirus in 2003, and six years later was awarded a Croucher Senior Medical Research Fellowship to work on novel therapeutic strategies for influenza.